<DOC>
	<DOC>NCT01621217</DOC>
	<brief_summary>- To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region - To evaluate acute toxicity - To evaluate late toxicity - To evaluate response rate - To evaluate recurrence free survival - To evaluate overall survival</brief_summary>
	<brief_title>Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (&gt;4 cm) - T4 N0-3 M0 or Any T N2-3 M0</brief_title>
	<detailed_description />
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Age over 18 years Histologically or cytologically confirmed squamous cell cancer of the anal region (anal canal or anal margin or distal rectum) Stage T2 (≥4 cm) T4 N03 M0 or any T N23 M0 ECOG performance status 01 Hb &gt; 100 g/L ANC &gt; 1.5 x 10 9/L Platelets ≥ 100 x 10 9/L Creatinine &lt; 1.5 x ULN Bilirubin &lt; 1.5 x ULN ALAT &lt; 3.0 x ULN Competent to comprehend, sign and date an approved informed consent form Previous pelvic irradiation Previous chemotherapy for anal cancer Previous malignancy within the last 5 years, except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix uteri Pregnant or nursing females or patients of childbearing potential not using adequate methods of birth control Patients with active infections or any other serious underlying medical condition, which would impair the ability of the patients to receive the protocol treatment Known hypersensitivity to any of the components of the treatment Clinically significant cardiovascular disease, e.g. cardiac failure (&lt;12 months before treatment start), unstable angina, congestive heart failure, arrythmia requiring medication, or uncontrolled hypertension Known positive test for hepatitis C virus, chronic active hepatitis B infection Known HIV infection Any other condition or therapy which in the investigator´s opinion may pose a risk to the patient or interfere with the study objectives Any investigational agent within 30 days before enrolment Surgery (excluding diagnostic biopsy or central venous catheter placement) and/or radiotherapy within 28 days prior to inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anal cancer</keyword>
	<keyword>Locally advanced anal cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>5-fluoruracil</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>